Chloroguanide metabolism in relation to the efficacy in malaria prophylaxis and the S-mephenytoin oxidation in Tanzanians

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 3, 1996, Pages 304-311

  Skjelbo, Erik ^a   Mutabingwa, Theonest K ^b   Bygbjerg, Ib ^b   Nielsen, Karin K ^b   Gram, Lars F ^b   Brøsen, Kim ^b  

^a IMB   (Denmark)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; CYCLOGUANIL; CYTOCHROME P450; DRUG METABOLITE; MEPHENYTOIN; PROGUANIL;

ADULT; AGED; ARTICLE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG METABOLISM; ENANTIOMER; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN EXPERIMENT; MALARIA CONTROL; MALE; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PHENOTYPE; PRIORITY JOURNAL; STEREOSPECIFICITY; TANZANIA;

ADULT; AGED; ANTICONVULSANTS; ANTIMALARIALS; ARYL HYDROCARBON HYDROXYLASES; CHLOROGUANIDE; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; HUMANS; MALARIA; MALE; MEPHENYTOIN; MIDDLE AGED; MIXED FUNCTION OXYGENASES; OXIDATION-REDUCTION; TANZANIA;

EID: 0029960882     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)80008-7     Document Type: Article

References (30)

1. Fogh S, Jepsen S, Effersøe P. Chloroquine-resistant plasmodium falciparum malaria in Kenya. Trans R Soc Trop Med Hyg 1979;73:228-9.
2. Hawking F, Perry WLM. Activation of paludrine. Br J Pharmacol 1948;3:320-5.
3. Carrington HC, Crowther AF, Davey DG, Levi AA, Rose FL. A metabolite of "Paludrine" with high antimalarial activity. Nature 1951;168:1080.
4. Ward SA, Watkins WM, Mberu E, et al. Inter-subject variability in the metabolism of proguanil to the active metabolite cycloguanil in man. Br J Clin Pharmacol 1989;27:781-7.
5. Watkins WM, Mberu EK, Nevill CG, Ward SA, Breckenridge AM, Koech DK. Variability in the metabolism of proguanil to the active metabolite cycloguanil in healthy Kenyan adults. Trans R Soc Trop Med Hyg 1990;84:492-5.
6. Helsby NA, Ward SA, Edwards G, Howells RE, Breckenridge AM. The pharmacokinetics and activation of proguanil in man: consequences of variability in drug metabolism. Br J Clin Pharmacol 1990;30: 593-8.
7. Helsby NA, Ward SA, Howells RE, Breckenridge AM. In vitro metabolism of the biguanide antimalarials in human liver microsomes: evidence for a role of the mephenytoin hydroxylase (P450MP) enzyme. Br J Clin Pharmacol 1990;30:287-91.
8. Ward SA, Helsby NA, Skjelbo E, Brøsen K, Gram LF, Breckenridge AM. The activation of the biguanide antimalarial proguanil co-segregates with the mephenytoin oxidation polymorphism - a panel study. Br J Clin Pharmacol 1991;31:689-92.
9. Funck-Brentano C, Bosco O, Jacqz-Aigrain E, Keundjian A, Jaillon P. Relation between chloroguanide bioactivation to cycloguanil and the genetically determined metabolism of mephenytoin in humans. CLIN PHARMACOL THER 1992;51:507-12.
10. Brøsen K, Skjelbo E, Flachs H. Proguanil metabolism is determined by the mephenytoin oxidation polymorphism in Vietnamese living in Denmark. Br J Clin Pharmacol 1993;36:105-8.
11. Wrighton SA, Stevens JC, Becker GW, Vanden-Branden M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and S-mephenytoin 4′-hydroxylation. Arch Biochem Biophys 1993;306:240-5.
12. Goldstein JA, Faletto MB, Romkes-Sparks M, et al. Evidence that CYP2C19 is the major (S)-mephenytoin 4′-hydroxylase in humans. Biochemistry 1994;33:1743-52.
13. de Morais SMF, Wilkinson GR, Blaisdell J, Nakamura K, Meyer UA, Goldstein JA. The major genetic defect responsible for the polymorphism of S-mephenytoin metabolism in humans. J Biol Chem 1994;269:15419-22.
14. de Morais SMF, Wilkinson GR, Blaisdell J, Meyer UA, Nakamura K, Goldstein JA. Identification of a new genetic defect responsible for the polymorphism of S-mephenytoin metabolism in Japanese. Mol Pharmacol 1994;46:594-8.
15. Alván G, Bechtel P, Iselius L, Gundert-Remy U. Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 1990;39:533-7.
16. Jurima M, Inaba T, Kadar D, Kalow W. Genetic polymorphism of mephenytoin p(4′)-hydroxylation: difference between Orientals and Caucasians. Br J Clin Pharmacol 1985;19:483-7.
17. Nakamura K, Goto F, Ray WA, et al. Interethnic differences in genetic polymorphism of debrisoquin and mephenytoin hydroxylation between Japanese and Caucasian populations. CLIN PHARMACOL THER 1985;38:402-8.
18. Mutabingwa TK, Malle LN, de Geus A, Oosting J. Malaria chemosuppression in pregnancy; I: the effect of chemosuppressive drugs on maternal parasitaemia. Trop Geogr Med 1993;45:6-14.
19. Mutabingwa TK. Studies on malaria chemosuppression during pregnancy in Tanzania [Thesis]. Amsterdam: University of Amsterdam; 1993. 131 p.
20. Zhang Y, Blouin RA, McNamara PJ, Steinmetz J, Wedlund PJ. Limitation to the use of the urinary S-/R-mephenytoin ratio in pharmacogenetic studies. Br J Clin Pharmacol 1991;31:350-2.
21. Sanz EJ, Villén T, Alm C, Bertilsson L. S-Mephenytoin hydroxylation phenotypes in a Swedish population determined after coadministration with debrisoquin. CLIN PHARMACOL THER 1989;45: 495-9.
22. Wedlund PJ, Aslanian WS, McAllister CB, Wilkinson GR, Branch RA. Mephenytoin hydroxylation deficiency in Caucasians: frequency of a new oxidative drug metabolism polymorphism. CLIN PHARMACOL THER 1984;36:773-80.
23. Drøhse A, Bathum L, Brøsen K, Gram LF. Mephenytoin and sparteine oxidation: genetic polymorphism in Denmark. Br J Clin Pharmacol 1989; 27:620-5.
24. Clasen K, Madsen L, Brøsen K, Albøge K, Misfeldt S, Gram LF. Sparteine and mephenytoin oxidation: genetic polymorphisms in East and West Greenland. CLIN PHARMACOL THER 1991;49:624-31.
25. Pollock BG, Perel JM, Kirshner M, Altieri LP, Yeager AL, Reynolds III CF. S-Mephenytoin 4-hydroxylation in older Americans. Eur J Clin Pharmacol 1991;40:609-11.
26. Iyun AO, Tucker GT, Woods HF, Lennard MS. The 4-hydroxylation of S-mephenytoin in Nigerians: a population study. In: Ingelman-Sundberg M, Gustafsson JA, Orrenius S, eds. Eighth International Symposium: Microsomes and Drug Oxidations. Stockholm: Karolinska Institutet, 1990.
27. Masimirembwa C, Bertilsson L, Johansson I, Hasler JA, Ingelman-Sundberg M. Phenotyping and genotyping of S-mephenytoin hydroxylase (cytochrome P4502C19) in a Shona population of Zimbabwe. CLIN PHARMACOL THER 1995;57:656-61.
28. Brøsen K, de Morais SMF, Meyer UA, Goldstein JA. A multifamily study on the relationship between CYP2C19 genotype and S-mephenytoin oxidation phenotype. Pharmacogenetics 1995;5:312-7.
29. Birkett DJ, Rees D, Andersson T, Gonzales FJ, Miners JO, Veronese ME. In vitro proguanil activation to cycloguanil by human liver microsomes is mediated by CYP3A isoforms as well as by S-mephenytoin. Br J Clin Pharmacol 1994;37:413-20.
30. Lemnge MM. Malaria and filariasis at Magoda Village in northeastern Tanzania: epidemiology, Maloprim malaria prophylaxis and estimation of blood Maloprim levels [Thesis]. Copenhagen: University of Copenhagen; 1995. 123 p.